Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04703790 · ClinicalTrials.gov registry record
Acceptability of a COVID-19 Vaccine Among US Adults Over Two Time Periods
A clinical trial, sponsored by Columbia University.
- Completed
- Registry status
- 1,208
- Enrollment target
NCT04703790: Completed study, sponsored by Columbia University.
NCT04703790 is a clinical trial that has completed, run by Columbia University. The registered enrollment target is 1,208 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04703790 has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 1,208 participants
- Enrollment target
Study Summary
The overall purpose of this study is to address the factors associated with an individual's personal willingness to get the vaccine and attitudes about potential public policy approaches to implementation of a Coronavirus Disease 2019 (COVID-19) vaccine. Additionally, to evaluate how these attitudes change over time. The 1200 participants will be recruited by Ipsos (Ipsos KnowledgePanel®) from their nationally representative panel to participate in a survey at Time 1 and 1 year later. The information collected will include demographics, health status, household composition, experiences with COVID-19, attitudes about vaccines in general, COVID-19 vaccine specific attitudes, willingness to get a COVID-19 vaccine acceptability, and attitudes regarding COVID-19 vaccine mandates. The investigators anticipate that those who live in urban areas and who are older, have greater knowledge of COVID-19, who have known someone who was hospitalized for COVID-19, and have generally positive attitudes about vaccines will be more willing to get a vaccine. The primary reasons for willingness will be personal safety and desire to return to normal activities. The investigators also anticipate that those who vary on socio-demographics (e.g., live in urban areas, have more liberal political views), have greater knowledge of COVID-19, who have known someone who was hospitalized for COVID- 19, and have generally positive attitudes about vaccines will be more supportive of mandatory vaccination strategies. The investigators anticipate that attitudes will change over time in response to the current status of the pandemic and of available data about the vaccine's efficacy and safety.
Primary Outcome
Participants vaccination status or intent to get vaccinated for COVID-19 will be measured via survey items.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,208 participants |
| Start Date | 2021-04-07 |
| Est. Completion | 2022-02-18 |
What the finished NCT04703790 record still lists
NCT04703790 is an observational study that tracks outcomes without assigning an intervention. Its 1,208 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT04703790 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04703790 about?
NCT04703790 is a clinical study titled "Acceptability of a COVID-19 Vaccine Among US Adults Over Two Time Periods". The overall purpose of this study is to address the factors associated with an individual's personal willingness to get the vaccine and attitudes about potential public policy approaches to implementation of a Coronavirus Disease 2019 (COVID-19) vaccine. Additionally, to evaluate how these attitudes...
What is the current status of trial NCT04703790?
This trial is currently completed. The enrollment target is 1,208 participants. The study started on 2021-04-07. Estimated completion is 2022-02-18.
Who is sponsoring clinical trial NCT04703790?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05946213 · 1,209 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- NCT06535854 · 1,205 participants · NA
Prevail Global Study
- NCT07223593 · 1,205 participants · Phase 3
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI